fda warning letters compounded semaglutide october 2025 issued 30 to telehealth companies for false and misleading claims about GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading Compounded Semaglutide & Tirzepatide 2025:

Reconstitution: This product arrives as a lyophilized powder

Its not like its only delivered to the Eli Lilly plant or wherever a drug is being made

Research in people with type 2 diabetes has found that GLP-1 users have a higher chance of gallbladder and bile duct problems compared with those on other diabetes medications

Statistical analysis was performed in situ within the TriNetX platform

When your body enters a steep caloric deficit especially a rapid one it does not selectively burn fat

Conversely, if semaglutide impairs levothyroxine absorption through delayed gastric emptying, TSH could rise, signaling the need for dose increases or timing adjustments